Jeroen B. Van Beek

Jeroen B. Van Beek is a declared insider at 2 companies (senior executive); the most frequent names are Kalaris Therapeutics, Inc. and Tricida, Inc. We count 51 filings; the first trade dates from 2 July 2018 and the latest from 16 November 2022.

Market trades split into 2 purchases (€129k) and 44 sales (€5.1M). Sales outweigh purchases by €5.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 4 share grants. 2022 to date brings no purchases and 15 sales.

On 18 November 2022 came the latest disclosure, an open-market sale for €116k in Kalaris Therapeutics, Inc. The last purchase on record was published on 5 August 2020, which is 2,287 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.